GERRESHEIMER AG

Gerresheimer AG’s €1 bn debt‑backed divestiture and supportive AGM signal a focused turnaround for the specialty packaging firm—what it means for investors.

Gerresheimer AG sees leadership change, Q1 2026 revenue rise 1% yet EBITDA slumps 17 m, amid market volatility and investor scrutiny.

Gerresheimer AG discloses European‑wide voting rights, boosting investor transparency and confidence in its life‑science container business.

Gerresheimer AG verkauft Kunststoffverpackungen an Apax – stärkt Fokus auf Glasverpackungen für Pharma & Medizin, steigert Aktienkurs.

Gerresheimer AG shifts voting‑rights after US consortium stake move – discover what this could mean for its strategy, governance, and stock outlook.

Gerresheimer AG: a resilient life‑science supplier poised for double‑digit growth in injectable & biologic packaging—current dip may signal a long‑term value play.

Gerresheimer AG discloses a voting‑rights announcement and a short‑sale position, revealing recent shareholder activity and market sentiment in the life‑sciences sector.

Gerresheimer AG’s stock is under intense short‑selling pressure, revealing market doubts and volatility; explore why investors are watching this healthcare player.

Gerresheimer AG’s plunge: accounting scandals, debt restructuring, and a rejected €41 takeover bid leave investors wary, showing how missteps erode value.

Gerresheimer AG faces investor uncertainty after delayed 2025 reports, a postponed shareholder meeting, credit talks, and the sale of its U.S. unit—yet its specialty glass business still holds long‑term growth potential.